Key facts
- TMA (Massachusetts)’s last known valuation is $12.4M (Jul 2025).
- It has raised $4.0M; the latest was Equity Crowdfunding ($3.9M) in Jul 2025.
- Notable investors include Creative Destruction Lab, Service Provider Capital, Lighthouse Labs (Richmond), Springhood, StartUp Health.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for TMA (Massachusetts)
- ·The full record, as it builds
Funding rounds
No funding rounds for TMA (Massachusetts) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TMA (Massachusetts)
Operator of a clinical decision support platform intended to drive the use of clinical genomics to deliver precision medicine at scale. The company's platform powers precision medicine for rare disease research and patient care by creating personalized reports based on history and health goals, enabling doctors to make medical decisions quickly based on reports.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 9
- Website
- sunstonehealth.com/
- Ownership
- Privately Held (backing)
TMA (Massachusetts) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TMA (Massachusetts) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TMA (Massachusetts) in its N-PORT filings yet. We sweep new filings monthly.